Anti-programmed cell death-1 (PD-1) monoclonal antibodies in treating advanced melanoma

Discovery Medicine

Volumn 19, Issue 106, 2015, Pages 393-401

  Metcalfe, Whitney ^a   Anderson, Jaime ^a   Trinh, VanAnh ^a   Hwu, Wen Jen ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI PD1 MONOCLONAL ANTIBODY; CARBOPLATIN; DACARBAZINE; IPILIMUMAB; MONOCLONAL ANTIBODY; NIVOLUMAB; PACLITAXEL; PEMBROLIZUMAB; TEMOZOLOMIDE; UNCLASSIFIED DRUG; PROGRAMMED DEATH 1 RECEPTOR;

ACUTE KIDNEY FAILURE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL DEATH; CELL PROLIFERATION; CELLULAR IMMUNITY; CHEMOTHERAPY; COLITIS; CYTOTOXIC T LYMPHOCYTE; DIARRHEA; DISEASE COURSE; DRUG DOSE ESCALATION; ENDOCRINE DISEASE; FATIGUE; HUMAN; HYPERTRANSAMINASEMIA; IMMUNOLOGICAL TOLERANCE; IMMUNOSURVEILLANCE; KIDNEY FAILURE; MAXIMUM TOLERATED DOSE; MELANOMA; PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; PROGRESSION FREE SURVIVAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; SOLID TUMOR; TUMOR REGRESSION; CANCER STAGING; CLINICAL TRIAL (TOPIC); IMMUNOLOGY; PATHOLOGY; SKIN TUMOR;

ANTIBODIES, MONOCLONAL; CLINICAL TRIALS AS TOPIC; HUMANS; MELANOMA; NEOPLASM STAGING; PROGRAMMED CELL DEATH 1 RECEPTOR; SKIN NEOPLASMS;

EID: 84940498365     PISSN: 15396509     EISSN: 19447930     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Agarwala SS. Current systemic therapy for metastatic melanoma. Expert Rev Anticancer Ther 9:587-595, 2009.
2. Atkins MB, Lotze MT, Dutcher JP, Fisher RI, Weiss G, Margolin K, Abrams J, Sznol M, Parkinson D, Hawkins M, Paradise C, Kunkel L, Rosenberg SA. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 17(7):2105-2116, 1999.
3. Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH, Stankevich E, Pons A, Salay TM, McMiller TL, Gilson MM, Wang C, Selby M, Taube JM, Anders R, Chen L, Korman AJ, Pardoll DM, Lowy I, Topalian SL. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 28(19):3167-3175, 2010.
4. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, Hogg D, Lorigan P, Lebbe C, Jouary T, Schadendorf D, Ribas A, O'Day SJ, Sosman JA, Kirkwood JM, Eggermont AM, et al. Improved survival withvemurafenibin melanoma with BRAF V600E mutation. N Engl J Med 364(26):2507-2516, 2011.
5. Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, Wolchok JD, Hersey P, Joseph RW, Weber JS, Dronca R, Gangadhar TC, Patnaik A, Zarour H, Joshua AM, Gergich K, Elassaiss-Schaap J, Algazi A, Mateus C, Boasbert P, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 369(2):134-144, 2013.
6. Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, Millward M, Rutkowski P, Blank CU, Miller WH Jr, Kaempgen E, Martín-Algarra S, Karaszewska B, Mauch C, Chiarion-Sileni V, Martin AM, Swann S, Haney P, Mirakhur B, Guckert ME, Goodman V, et al. Dabrafenibin BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 380(9839):358-365, 2012.
7. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AH, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbe C, Peschel C, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363(8):711-723, 2010.
8. Jang S, Atkins MB. Which drug, and when, for patients with BRAF-mutant melanoma? Lancet Oncol 14(2):e60-e69, 2013.
9. Joseph R, Elassaiss-Schaap J, Wolchok JD, Joshua AM, Ribas A, Hodi FS, Hamid O, Robert C, Daud A, Hwu WJ, Kefford R, Hersey P, Weber JS, Patnaik A, Dolled-Filhart M, Emancipator K, Kang SP, Ebbinghaus S, Anderson K, Gangadhar TC. Baseline tumor size and PD-L1 expression are independently associated with clinical outcomes in patients with metastatic melanoma treated with pembrolizumab (MK-3475). Presented at the Society for Melanoma Research Congress, Zurich, Switzerland, 2014.
10. National Comprehensive Cancer Network. NCCN guidelines: melanoma, version 3. http://www.nccn.org/professionals/physician_gls/pdf/melanoma.pdf. 2015. (Accessed Apr. 2, 2015.)
11. Okudaira K, Hokari R, Tsuzuki Y, Okada Y, Komoto S, Watanabe C, Kurihara C, Kawaguchi A, Nagao S, Azuma M, Yagita H, Miura S. Blockade of B7-H1 or B7-DC induces an anti-tumor effect in a mouse pancreatic cancer model. Int J Oncol 35(4):741-749, 2009.
12. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nature 12:252-264, 2012.
13. Patnaik A, Kang SP, Tolcher AW, Hamid O, Rasco D, Ribas A, Papadopoulos K, Robert C, Beeram M, Drengler R, Chen C, Smith L, Perez C, Gergich K, Lehnert M, et al. Phase I study of MK-3475 (anti-PD-1 monoclonal antibody) in patients with advanced solid tumors. Presented at the ASCO Annual Meeting, Chicago, IL, USA, 2012.
14. Ribas A, Puzanov I, Dummer R, Daud A, Schadendorf D, Robert C, Schachter J, Pavlick A, Gonzalez R, Hodi FS, Cranmer LD, Blank C, O'Day SJ, Ascierto PA, Salama AKS, Li NX, Zhou W, Lis J, Ebbinghause S, Kang, SP, et al. A randomized controlled comparison of pembrolizumab and chemotherapy in patients with ipilimumab-refractory melanoma. Presented at the Society for Melanoma Research Congress, Zurich, Switzerland, 2014.
15. Robert C, Thomas L, Bondarenko I, O'Day S, Weber J, Garbe C, Lebbe C, Baurain JF, Testori A, Grob JJ, Davidson N, Richards J, Maio M, Hauschild A, Miller WH Jr, Gascon P, Lotem M, Harmankaya K, Ibrahim R, Francis S, el al. Ipilimumabplus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 364(26):2517-2526, 2011.
16. Robert C, Ribas A, Wolchock JD, Hodi FS, Hamid O, Kefford R, Weber JS, Joshua AM, Hwu WJ, Gangadhar TC, Patnaik A, Dronca R, Zarour H, Joseph RW, Boasberg P, Chmielowski B, Mateus C, Postow MA, Gergich K, Elassaiss-Schaap J, et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet 384:1109-1117, 2014a.
17. Robert C, Joshua AM, Weber JS, Ribas A, Hodi FS, Kefford R, Daud A, Wolchok JD, Hwu WJ, Gangadhar TC, Patnaik A, Hersey P, Dronca R, Zarour H, Ge Y, Lindia JA, Giannotti M, Ebbinghaus S, Kang SP, Hamid O. Pembrolizumab (MK-3475) for advanced melanoma: randomized comparison of two dosing schedules. Presented at the ESMO Annual Meeting, Madrid, Spain, 2014b.
18. Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, Hassel JC, Rutkowski P, McNeil C, Kalinka-Warzocha E, Savage KJ, Hernberg MM, Lebbé C, Charles J, Mihalcioiu C, Chiarion-Sileni V, Mauch C, Cognetti F, Arance A, Schmidt H, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 372(4):320-323, 2015.
19. Schadendorf D, Hodi FS, Robert C, Weber JS, Margolin K, Hamid O, Patt D, Chen TT, Berman DM, Wolchok JD. Pooled analysis of long-term survival data from phase II and phase III trials ofipilimumabin unresectable or metastatic melanoma. J Clin Oncol, epub ahead of print, Feb. 9, 2015.
20. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin 65(1):5-29, 2015.
21. Sznol M, Kluger H, Callahan MK, Postow MA, Gordon RA, Segal NH, Rizvi NA, Lesokhin AM, Atkins MB, Kirkwood JM, Burke MM, Ralabate A, Rivera A, Kronenberg SA, Agunwamba BU, Feely W, Hong Q, Krishnan S, Wolchok JD. Survival, response duration, and activity by BRAF mutation status of nivolumab and ipilimumab concurrent therapy in advanced melanoma. Presented at the ASCO Annual Meeting, Chicago, IL, USA, 2014.
22. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ, Horn L, Drake CG, Pardoll DM, Chen L, Sharfman WH, Anders RA, Taube JM, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366(26):2443-2454, 2012.
23. Topalian SL, Sznol M, McDermott DF, Kluger HM, Carvajal RD, Sharfman WH, Brahmer JR, Lawrence DP, Atkins MB, Powderly JD, Leming PD, Lipson EJ, Puzanov I, Smith DC, Taube JM, Wigginton JM, Kollia GD, Gupta A, Pardoll DM, Sosman JA, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 32(10):1020-1030, 2014.
24. Weber JS, Dummer R, de Pril V, Lebbe C, Hodi FS. Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab. Cancer 119:1675-1682, 2013.
25. Weber JS, D'Angelo SP, Minor D, Hodi FS, Gutzmer R, Neyns B, Hoeller C, Khushalani NI, Miller WH Jr, Lao CD, Linette GP, Thomas L, Lorigan P, Grossmann KF, Hassel JC, Maio M, Sznol M, Ascierto PA, Mohr P, Chmielowski B, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 16(4):375-384, 2015.
26. Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, Segal NH, Ariyan CE, Gordon RA, Reed K, Burke MM, Caldwell A, Kronenberg SA, Agunwamba BU, Zhang X, Lowy I, Inzunza HD, Feely W, Horak CE, Hong Q, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 369(2):122-133, 2013.
27. Zhou Q, Xiao H, Lin Y, Peng Y, Hong Y, Yagita H, Chandler P, Munn DH, Mellor A, Fu N, He Y. Blockade of programmed death-1 pathway rescues the effector function of tumor-infiltrating T cells and enhances the antitumor efficacy of lentivector immunization. J Immunol 185(9):5082-5092, 2010.